2022 will see our most anticipated technology release to date: the BnTx INTERACT Patient app
Sydney, Australia – 25 January 2022 This year, BnTx INTERACT will launch an app for patients, which will be fully integrated with the clinic software. The app will be available on desktop, mobile, tablet, and watch, and aims to collect passive and active data in between consults.
The app will enable the transfer of information, such as treatment effectiveness and symptom progression, between physician and patient remotely. Patients can enter their symptoms, medications and quality of life scores via the app in between treatment. This data is accessible to the physician in real-time or prior to a consultation.
Other features will include appointment reminders, visual scales and dashboards of patients' treatment, and a portal for educational material.
BnTx INTERACT CEO, Anthony Avvenevole says the app will be a step forward in the migraine and botulinum toxin treatment space.
"Technology can now allow accurate symptoms tracking to better inform treatment decisions. The accumulation and presentation of data is entering a new age for physicians, an age which will accommodate patient expectations and involvement; perhaps, impacting motivation in sometimes difficult-to-treat conditions."
The BnTx INTERACT patient app will be released in 2022. The clinic software is available now for clinics and physicians of botulinum toxin.
To stay up to date with the release of the patient app, subscribe to our newsletter.
About BnTx INTERACT
Developed by healthcare technology company, INTERACT Technology Group, BnTx INTERACT is cloud-based healthcare software and online tool for clinics specialising in the injection of botulinum toxin across various conditions such as cervical dystonia, chronic migraine and spasticity. Designed by leading Neurologist, Professor Con Yiannikas and refined with input from other leading injectors, the software contains comprehensive clinical resources such as interactive 3D anatomy with movable muscle layers, surface anatomy, cadaver and EMG footage as well as case studies. In addition, simple inputs automatically generate a report for referrers, and a data suite allows you to track key aspects of treatment over time.
For more information: www.bntxinteract.com
Media Contacts:
Holly Whittaker
Communications Manager
INTERACT Technology Group
Anthony Avvenevole
CEO
BnTx INTERACT